Europe Multiple Sclerosis Treatment Market: Industry Analysis and Forecast (2024-2030)

Europe Multiple Sclerosis Treatment Market Overview

Multiple sclerosis (MS) affects function in cognitive, emotional, motor, sensory, or visual areas and occurs as a result of a person’s immune system attacking their brain and spinal cord.

 

The report has covered Europe's multiple sclerosis treatment market dynamics which includes the growth drivers, opportunities, restraints, and challenges. The major factors that affect and hinder market growth have been analyzed in the report. The report has also covered the nuanced elements of the European multiple sclerosis treatment market and analyses the market leader’s strategies to give insights to the stakeholders.

 

The Europe Multiple Sclerosis Treatment Market is expected to boost during the forecast period owing to higher demand in the European Countries. Recent developments, Mergers, and acquisitions of key players are analyzed in the Report to gain insights into the European Multiple Sclerosis Market.

 

• The European Union is now funding the international research consortium BEHIND-MS as part of its HORIZON Europe program, which aims to clarify these associations to identify specific biomarkers and targeted therapeutic approaches.
• More than 700,000 people suffer from multiple sclerosis (MS) in Europe. The occurrence of multiple Sclerosis is more likely in women than men.

 

To get more Insights: Request Free Sample Report

 

Europe Multiple Sclerosis Treatment Market Dynamics

Driving Forces Behind the Booming Multiple Sclerosis Treatment Market in Europe

The Rapid development in the research and development are creating huge potential for the market leaders to invest in the market. The major factor driving the market is advancement in the technologies of treatment such as drug formulation etc., which has led to the market growth in Europe. The increase in the awareness of the Multiple Sclerosis Treatment Market in Europe has propelled the market growth.

 

Growing public awareness of Multiple Sclerosis (MS) and its escalating prevalence MS is a chronic inflammatory disease of the central nervous system that impairs normal brain, spinal cord, and optic nerve functioning. In Europe, MS diagnoses have increased, and earlier diagnosis and treatment are a result of increased public awareness of the illness that has influenced the market growth in Europe. Additionally, the rising demand for healthcare facilities in Europe has propelled the market growth.

 

Challenges in Multiple Sclerosis Treatment Selection and Awareness in Europe

The growing list of approved treatments for MS has made selecting the optimal agent for an individual patient more challenging. Recent evidence suggests that early treatment with highly effective therapy has been associated with a lower risk of disability progression and conversion to secondary progressive MS (34) as a result some patients get an unnecessary risk of severe adverse effects such as infections, cardiac dysfunction, liver damage, or an increased risk of autoimmune diseases.

 

In Addition, lack of awareness of MS symptoms among the general public (68%), “lack of awareness of MS symptoms among health care professionals (59%), and lack of availability of health care professionals with the knowledge to diagnose MS has hindered the market growth in Europe. The clinical and pathological heterogeneity of MS makes treatment difficult. Treatment is further hampered by untoward adverse effects caused by immune suppression that has led to steady growth of the market.

 

Europe Multiple Sclerosis Treatment Market Segment Analysis

Based on Treatment, Immunomodulators segments dominate the market in Europe and are expected to maintain their dominance during the forecast period. Immunomodulators are medicines that change your immune system so it works more effectively. It includes treatments that increase or decrease your immune response. Immunomodulators treat various conditions, including cancer and autoimmune diseases.

 

Teriflunomide is an oral immunomodulatory agent that elicits anti-inflammatory effects by inhibiting dihydroorotate dehydrogenase, a mitochondrial enzyme involved in pyrimidine synthesis. It is indicated for relapsing forms of MS. Immunomodulatory drugs modify the response of the immune system by either stimulation or suppression. These drugs have been changing the landscape of medical treatment in cancer, auto-immune and infectious diseases, and in the disease prevention field, with vaccines. Immunomodulators exist in the form of proteins, oligonucleotides, biologics, bispecific antibodies, gene therapy, and others.

Europe Multiple Sclerosis Treatment Market Regional Analysis

Germany holds the highest number of shares and is expected to grow with an increasing CAGR through the forecast year.  Germany has one of the largest pharmaceutical industries owing to which there is improved diagnosis and advancements in healthcare infrastructure for Multiple Sclerosis Treatment. In Germany, healthcare spending is higher than the European Union (EU) average and the country has the highest per capita spending on healthcare in the EU.

 

Germany has near universal health coverage through compulsory health insurance that is primarily based on a public insurance scheme, with low out-of-pocket spending. Though, care is noted to be fragmented and uncoordinated owing to a lack of digitization. Increased access to specialized care and support, Germany has established new MS centers and a Master in MS Management. Additionally, the MS Society has supported the development of new patient empowerment programs to better support people with MS

 

• In 2023, Multiple sclerosis (MS) is a complex neurodegenerative disease affecting approximately 250,000 of the 83.7 million people in Germany.

 

Italy is the fastest-growing country in Europe owing to the high prevalence of Multiple Sclerosis Treatment. The Italian Multiple Sclerosis Society (AISM) is the only organization in Italy that addresses every aspect of multiple sclerosis (MS), through advocating for the rights of people with MS and providing services and through orienting, promoting, and financing scientific research.

 

• Multiple sclerosis (MS) is a complex neurodegenerative disease affecting approximately 126,000 of the 60.4 million people in Italy in 2023.

 

Similarly, France, the United Kingdom, Sweden, etc., are experiencing steady growth in the Multiple Sclerosis treatment market owing lack of awareness in the countries.

Europe Multiple Sclerosis Treatment Market Competitive Landscape

• In February 2024, Roche Pharma launches a new drug for multiple sclerosis treatment in India. With the launch of the new drug, the global pharma company hopes to expand its neurology portfolio and cater to the untapped needs of patients facing the disease in India. 
• In December 2023, Merck KGaA suffered a major blow as the MS drug failed in late-stage trials. Merck was seen as ahead of Sanofi SASY.PA, Novartis NOVN.S, and Roche ROG.S in a four-way race to develop more targeted MS drugs in a class known as Bruton’s tyrosine kinase (BTK) inhibitors.
• In March 2022, Novartis announced today that the European Commission has approved Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined by clinical or imaging features. Kesimpta is a targeted, precisely dosed, and delivered B-cell therapy that has shown superior efficacy with a similar safety profile compared with teriflunomide, a first-line treatment in MS2. Kesimpta is the first B-cell therapy that can be self-administered once monthly at home via the Sensoready autoinjector pen and can be a first-choice treatment option for patients with RMS.

Europe Multiple Sclerosis Treatment Market Scope
Market Size in 2023	USD 7.44 Bn.
Market Size in 2030	USD 11.87 Bn.
CAGR (2024-2030)	6.9%
Historic Data	2018 - 2022
Base Year	2023
Forecast Period	2024-2030
Segment Scope	By Treatment Immunosuppressants Humira Infliximab Immunomodulators Thalidomide Lenalidomide
	By Disease Stage Relapsing-Remitting Multiple Sclerosis (RRMS)  Secondary Progressive Multiple Sclerosis (SPMS)  Primary Progressive Multiple Sclerosis (PPMS)  Severe Relapsing-Remitting Multiple Sclerosis (RES)
	By End User Hospital and Clinics  Diagnostic Laboratories  Others
Country Scope	Germany United Kingdom Spain France Italy Belgium Sweden Poland Russia

 

Europe Multiple Sclerosis Treatment Market Key Players

1. Neuraxpharm Group
2. Novartis AG
3. Roche Holding AG
4. Merck KGaA
5. Sanofi
6. Bayer AG